189 related articles for article (PubMed ID: 35975974)
21. The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas.
Lam KY; Lo CY; Wat NM; Luk JM; Lam KS
J Clin Pathol; 2001 Jun; 54(6):443-8. PubMed ID: 11376017
[TBL] [Abstract][Full Text] [Related]
22. Demonstration of S-100 protein in sustentacular cells of phaeochromocytomas and paragangliomas.
Schroder HD; Johannsen L
Histopathology; 1986 Oct; 10(10):1023-33. PubMed ID: 3536711
[TBL] [Abstract][Full Text] [Related]
23. Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation.
Abdul Sater Z; Jha A; Hamimi A; Mandl A; Hartley IR; Gubbi S; Patel M; Gonzales M; Taïeb D; Civelek AC; Gharib AM; Auh S; O'Mara AE; Pacak K; Cypess AM
J Clin Endocrinol Metab; 2020 Apr; 105(4):1176-85. PubMed ID: 31903484
[TBL] [Abstract][Full Text] [Related]
24. Stathmin immunoreactivity in phaeochromocytomas and paragangliomas: differential expression between benign and malignant neoplasms.
Lin WC; Chen SC; Chuang YT; Kuo KL; Huang KH
Asian J Surg; 2011 Jan; 34(1):15-22. PubMed ID: 21515208
[TBL] [Abstract][Full Text] [Related]
25. SDHB and SDHD silenced pheochromocytoma spheroids respond differently to tumour microenvironment and their aggressiveness is inhibited by impairing stroma metabolism.
Martinelli S; Riverso M; Mello T; Amore F; Parri M; Simeone I; Mannelli M; Maggi M; Rapizzi E
Mol Cell Endocrinol; 2022 May; 547():111594. PubMed ID: 35149119
[TBL] [Abstract][Full Text] [Related]
26. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas.
Benn DE; Croxson MS; Tucker K; Bambach CP; Richardson AL; Delbridge L; Pullan PT; Hammond J; Marsh DJ; Robinson BG
Oncogene; 2003 Mar; 22(9):1358-64. PubMed ID: 12618761
[TBL] [Abstract][Full Text] [Related]
27. The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas).
Kaltsas GA; Papadogias D; Grossman AB
Front Horm Res; 2004; 31():61-75. PubMed ID: 14674305
[No Abstract] [Full Text] [Related]
28. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
[TBL] [Abstract][Full Text] [Related]
29. Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours.
Srirangalingam U; Khoo B; Walker L; MacDonald F; Skelly RH; George E; Spooner D; Johnston LB; Monson JP; Grossman AB; Drake WM; Akker SA; Pollard PJ; Plowman N; Avril N; Berney DM; Burrin JM; Reznek RH; Kumar VK; Maher ER; Chew SL
Endocr Relat Cancer; 2009 Jun; 16(2):515-25. PubMed ID: 19208735
[TBL] [Abstract][Full Text] [Related]
30. Differences in intraoperative and surgical outcomes between normotensive pheochromocytomas and sympathetic paragangliomas (PPGLs) and hypertensive PPGLs: results from the PHEO-RISK STUDY.
Araujo-Castro M; García Sanz I; Mínguez Ojeda C; Calatayud M; Hanzu F; Mora M; Vicente A; Blanco Carrera C; De Miguel Novoa P; López García MDC; Manjón-Miguélez L; Rodríguez de Vera P; Del Castillo Tous M; Barahona San Millán R; Recasens M; Tomé Fernández-Ladreda M; Valdés N; Gracia Gimeno P; Robles Lazaro C; Michalopoulou T; Álvarez Escolá C; García Centeno R; Lamas C
J Endocrinol Invest; 2023 Apr; 46(4):805-814. PubMed ID: 36323983
[TBL] [Abstract][Full Text] [Related]
31. New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.
Taïeb D; Pacak K
Trends Endocrinol Metab; 2017 Nov; 28(11):807-817. PubMed ID: 28867159
[TBL] [Abstract][Full Text] [Related]
32. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes.
Pasini B; Stratakis CA
J Intern Med; 2009 Jul; 266(1):19-42. PubMed ID: 19522823
[TBL] [Abstract][Full Text] [Related]
33. What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?
Papathomas TG; Suurd DPD; Pacak K; Tischler AS; Vriens MR; Lam AK; de Krijger RR
Endocr Pathol; 2021 Mar; 32(1):134-153. PubMed ID: 33433885
[TBL] [Abstract][Full Text] [Related]
34. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
35. LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.
Li H; Hardin H; Zaeem M; Huang W; Hu R; Lloyd RV
Ann Diagn Pathol; 2021 Dec; 55():151801. PubMed ID: 34461576
[TBL] [Abstract][Full Text] [Related]
36. Genetic Analysis and Clinical Characteristics of Hereditary Pheochromocytoma and Paraganglioma Syndrome in Korean Population.
Choi H; Kim KJ; Hong N; Shin S; Choi JR; Kang SW; Lee ST; Rhee Y
Endocrinol Metab (Seoul); 2020 Dec; 35(4):858-872. PubMed ID: 33397040
[TBL] [Abstract][Full Text] [Related]
37. Genetic Characteristics of Incidental Pheochromocytoma and Paraganglioma.
Zhang J; Li M; Pang Y; Wang C; Wu J; Cheng Z; Li X; Lu Z; Liu Y; Guo J; Chen X; He Y; Guan X; Xu X; Wang Y; Liu J; Guo W; Hou Y; Liu L; Jiang J; Gao X
J Clin Endocrinol Metab; 2022 Apr; 107(5):e1835-e1842. PubMed ID: 35106577
[TBL] [Abstract][Full Text] [Related]
38. Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma.
Murakami M; Sun N; Greunke C; Feuchtinger A; Kircher S; Deutschbein T; Papathomas T; Bechmann N; William Wallace P; Peitzsch M; Korpershoek E; Friemel J; Gimenez-Roqueplo AP; Robledo M; J L M Timmers H; Canu L; Weber A; R de Krijger R; Fassnacht M; Knösel T; Kirchner T; Reincke M; Karl Walch A; Kroiss M; Beuschlein F
Eur J Endocrinol; 2021 Jun; 185(1):179-191. PubMed ID: 33983135
[TBL] [Abstract][Full Text] [Related]
39. Identification of Novel Mutations and Expressions of
Islam F; Pillai S; Gopalan V; Lam AK
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33114456
[TBL] [Abstract][Full Text] [Related]
40. TOP2A Expression in Pheochromocytoma and Abdominal Paraganglioma: a Marker of Poor Clinical Outcome?
Solhusløkk Höse K; Stenman A; Svahn F; Larsson C; Juhlin CC
Endocr Pathol; 2023 Mar; 34(1):129-141. PubMed ID: 36656469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
